Skip to main content
. 2024 Nov 8;25(1):2425127. doi: 10.1080/15384047.2024.2425127

Table 3.

Major inhibitors of CypA and potential therapeutic strategies.

Inhibitors Mechanism Therapeutic Potential Targeted Cancer References
CsA PPIase activity Interference of CypA and CD147 binding, Induction of apoptosis Breast cancer, Lung adenocarcinoma 113,120
Debio-025 (Alisporivir) Crk signaling Non-immunosuppressive analogue of CsA, Potent antitumor and antimetastatic activity, Enhancing of tumor immunogenicity and anti-PD-1 therapy Breast cancer, Hepatitis C-hepatocellular carcinoma 121
Sanglifehrin A PPIase activity Binding to CypA with higher affinity than CsA Glioblastoma multiforme 66,122
SCY-635, NIM811 NS5A Non-immunosuppressive activity, Inhibition of hepatocarcinogenesis Hepatitis C-hepatocellular carcinoma 22
NV651 PPIase activity Non-immunosuppressive activity, inbibition of cell proliferation and tumor growth in vivo Hepatocellular carcinoma 123
23-demethyl 8, 13-deoxynargenicin (C9) MAPK signaling Inhibition of proliferation, migration, invasion and angiogenesis Gastric cancer 124
Melittin MMP-9 Inhibition of metastasis Breast cancer 125
RNA interference PPIase activity Inhibition of tumor growth, Enhancing of radiosensitivity Lung adenocarcinoma 116
  NF-κB signaling Inhibition of glioblastoma growth Glioblastoma 126
Blocking interaction CypA/CD147 interaction Inhibition of tumor growth, metastasis, invasion Hepatocellular carcinoma, breast cancer 100